by Eric Christianson | Dec 1, 2013 | Personal Stories From The Front Lines of Clinical Pharmacy
I recently saw an article posted on KevinMD.com that was written last year or so, it also prompted me to look at other articles similar to this. In the article, a medical student describes the situation where Coumadin is 15 dollars at one pharmacy and 4 dollars at...
by Eric Christianson | Nov 30, 2013 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
I’m going to cover sulfonylureas tonight; this class is a mainstay in the treatment Type 2 diabetes. Other than metformin, these drugs are probably the most frequent oral class used. The most frequent names that come to mind are glipizide, glimepiride, and...
by Eric Christianson | Nov 29, 2013 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
Today, it’s the DDP-4 inhibitors! DPP-4 inhibitors can be expensive which may limit their use from time to time. These drugs work to increase the amount of incretin in the body. You can look back at my post on Byetta/Victoza which should be under the diabetes...
by Eric Christianson | Nov 28, 2013 | Personal Stories From The Front Lines of Clinical Pharmacy
A few months back, I had this enlightening interaction with a nursing home resident: I was working away at a nurses’ station and this elderly gentleman strolls by in his wheel chair, telling me I must be a student (probably because I look like I’m 12). I said...
by Eric Christianson | Nov 27, 2013 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
I’m going to flip back to oral diabetes meds to cover a new agent that has recently been approved. It is a new class of diabetes med, but generally means it’s going to be quite expensive. This drug is Invokana (canagliflozin). It basically lowers glucose by causing an...
